Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Algernon Health Inc (OP:AGNPF)

0.0351 -0.0044 (-11.14%)
Streaming Delayed Price Updated: 12:40 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Algernon Health Inc

News headline image
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗
 
Via Benzinga
News headline image
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design ↗
 
Via Benzinga
News headline image
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
News headline image
DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study ↗
Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE:AGN) (FRANKFURT:AGW0), has completed a feasibility study and has finalized its clinical trial design... 
Via Benzinga
News headline image
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study ↗
 
Via Benzinga
News headline image
DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up ↗
Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous... 
Via Benzinga
News headline image
How To Finance A Psychedelics Business? Learn From These Four Companies ↗
Clearmind Medicine Announces Pricing of $3.5 Million Public Offering 
Via Benzinga
News headline image
Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment ↗
Canadian biopharma company Algernon Pharmaceuticals Inc. 
Via Benzinga
News headline image
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
News headline image
Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI ↗
In this new podcast, TDR Founder Shadd Dales interviewed Algernon Pharmaceuticals (OTC: AGNPF) CEO, Christopher Moreau. 
Via Benzinga
News headline image
Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program ↗
Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity.  
Via Benzinga
News headline image
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
News headline image
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
News headline image
Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program ↗
Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary. 
Via Benzinga
News headline image
Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose ↗
Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of 
Via Benzinga
News headline image
A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing ↗
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed 
Via Benzinga
News headline image
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One ↗
The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs. 
Via Benzinga
News headline image
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans ↗
Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
News headline image
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
News headline image
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon ↗
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. 
Via Benzinga
News headline image
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University ↗
Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc. 
Via Benzinga
News headline image
A Foundational Study On Stroke Is Ready. Here Is Why It's Important ↗
Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma 
Via Benzinga
News headline image
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment ↗
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin... 
Via Benzinga
News headline image
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution ↗
Biotech clinical-stage company Algernon Pharmaceuticals Inc. 
Via Benzinga
News headline image
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗
The Week In Psychedelics 
Via Benzinga
News headline image
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics ↗
Last Week In Psychedelics: 
Via Benzinga
News headline image
How To Invest In "Magic Mushrooms" (Psychedelics) ↗
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
News headline image
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
News headline image
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies ↗
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
News headline image
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform ↗
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.